🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for psoriasis

The Norwegian Antirheumatic Drug Register NCT01581294n/a6 sites📍 Drammen📍 Lillehammer📍 Førde Diakonhjemmet Hospital A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis NCT06807424Phase 3236 sites📍 Glendale📍 Mesa📍 Jonesboro Janssen Research & Development, LLC · Tests: Icotrokinra, Placebo Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis NCT07261306EARLY Phase 11 site📍 Lahore Lahore General Hospital · Tests: Methotrexate, Tofacitinib Novel Complex Radiodiagnostics of Peripherial Arthropathies NCT05657847n/a3 sites📍 Budapest📍 Budapest📍 Budapest Semmelweis University · Tests: Photon-counting detector-CT Evaluation of Patient Satisfaction and Therapeutic Impact Regarding Joint Consultation Rheumatologist/Dermatologist NCT04800289n/a1 site📍 Le Mans Centre Hospitalier le Mans · Tests: questionnaires HIPPOCRATES Prospective Observational Study NCT05858528n/a1 site📍 Oxford University of Oxford · Tests: PEST screening questionnaire Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea NCT06258668n/a2 sites📍 Seoul📍 Seoul Bristol-Myers Squibb · Tests: Deucravacitinib Swiss Dermatology Network of Targeted Therapies (SDNTT) NCT01706692n/a6 sites📍 Aarau📍 Basel📍 Bern Swiss Dermatology Network for Targeted Therapies · Tests: Adalimumab, Etanercept, Infliximab, Ustekinumab, Cyclosporine A Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases NCT06842316n/a1 site📍 Orléans Centre Hospitalier Régional d'Orléans · Tests: 1 blood sample, 40 mL (collection during a blood test, part of the standard of care for this disease) Retinal Capillary Vessel Density and Foveal Avascular Zone Size in Patients With Psoriatic Arthritis: A Case-Control Study. NCT07858591n/a1 site📍 Bursa Bursa Yuksek Ihtisas Training and Research Hospital · Tests: OCTA-SCP, OCTA-DCP, OCTA-RPC, OCTA-FAZ A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis NCT04772079Phase 365 sites📍 Ciudad Autonoma de Buenos Aires📍 Ciudad Autonoma de Buenos Aires📍 Buenos Aires Bristol-Myers Squibb · Tests: Deucravacitinib, Placebo matching deucravacitinib Walk and Talk: Connecting People With Psoriasis NCT06726213NA1 site📍 London Royal Free Hospital NHS Foundation Trust · Tests: Walk and talk Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet NCT06574178NA1 site📍 Sacramento University of California, Davis · Tests: Dietary Counseling A Pilot Study to Assess How Safe and Effective Oral Roflumilast is for Treating Moderate to Severe Psoriasis in Adults NCT07233291Phase 21 site📍 Al Mansurah Ahmed Ibrahim · Tests: Oral roflumilast A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis NCT07129382Phase 1, Phase 211 sites📍 Beijing📍 Beijing📍 Chengde Chipscreen Biosciences, Ltd. · Tests: CS32582 capsule（low dose） or matched placebo, CS32582 capsule（high dose） or matched placebo, CS32582 capsule（low dose）,… Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants NCT07258745Phase 11 site📍 Warsaw Chong Kun Dang Pharmaceutical · Tests: SKYRIZI, SKYRIZI, CKD-704 Deployment o the Multidisciplinary Prospective Cohort Imminent NCT04334031NA1 site📍 Lille University Hospital, Lille · Tests: Biobanking with genetic analysis, SF-12 questionnaire A Study to Assess Deucravacitinib Safety in Pregnancy NCT07017699n/a1 site📍 La Jolla Bristol-Myers Squibb · Tests: Deucravacitinib, Other systemic treatments for PsO Molecular Signatures in Inflammatory Skin Disease NCT03358693n/a1 site📍 Kiel Prof. Dr. Stephan Weidinger · Tests: Anti-TNF, Anti-IL12/23, Anti-IL17, Dupilumab, Anti-IL23 PALLAS Laser for Skin Diseases NCT07250997NA1 site📍 Szeged Szeged University · Tests: UVB laser treatment A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults NCT07290036Phase 163 sites📍 Peoria📍 Apple Valley📍 Covina UCB Biopharma SRL · Tests: Bimekizumab regimen 1 iv, Bimekizumab regimen 2 iv, Bimekizumab regimen 3 sc APACHE Cohort (A Psoriatic Arthritis CoHort) NCT03768271n/a3 sites📍 Créteil📍 Montpellier📍 Paris Assistance Publique - Hôpitaux de Paris A Study of WD-890 in Participants With Moderate-to-Severe Plaque Psoriasis NCT06912165Phase 21 site📍 Nanjing Zhejiang Wenda Pharma Technology LTD. · Tests: WD-890 tablet, WD-890 tablet, WD-890 tablet, Placebo Immune-Competent Cell Manifestations in Psoriatic Arthritis Achilles Tendons NCT03248284n/a2 sites📍 Odense📍 Silkeborg Odense University Hospital · Tests: Tendon biopsy procedure Glucocorticoid-induced Osteoporosis in Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis NCT02719314n/a1 site📍 Berlin Prof Dr Frank Buttgereit · Tests: Glucocorticoid treatment A Study of UA026 Tablets in Healthy Adult Subjects and Adult Subjects With Moderate to Severe Plaque Psoriasis NCT07038720Phase 11 site📍 Hangzhou Usynova Pharmaceuticals Ltd. · Tests: UA026, Placebo Novel Skin Barrier Product Versus Petrolatum for Skin Barrier Dysfunction NCT07183423NA1 site📍 Makati City Makati Medical Center · Tests: Novel barrier repair topical product, Petrolatum Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications NCT04846959n/a2 sites📍 Morrisville📍 Wilmington AbbVie · Tests: Risankizumab, Comparator Managing Psychological Distress Through Mindfulness-based CBT to Evaluate Its Effectiveness on Self-compassion Among Psoriasis Patients:The Mediating Role of Mental Health Locus of Control NCT07615257NA1 site📍 Rahim Yar Khan Islamia University of Bahawalpur · Tests: Mindfulness-Based Cognitive Therapy (MBCT), Usual Care Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis NCT07251998Phase 21 site📍 Shanghai Beijing InnoCare Pharma Tech Co., Ltd. · Tests: ICP-332 Tablets, ICP-332 Tablets, ICP-332 Tablets, ICP-332 Placebo Tablets
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy